SCHEMBL15031982

SCHEMBL15031982

Cc1ccccc1-c1n[nH]c(=O)c2cc(SCc3ccccc3)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
SCN9A Q15858 1/20 0.43
DAO P14920 2/20 0.42
S100A4 P26447 1/20 0.41
ROCK1 Q13464 2/20 0.41
LMNA P02545 3/20 0.40
RAB9A P51151 2/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.39
EGFR P00533 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15031922 0.87 MAOB (0.41) MAOAMAOBSCN9ADAOROCK1
SCHEMBL15010308 0.86 PDE4A (0.47) MAOAMAOBSCN9ADAORAB9A
SCHEMBL17824806 0.79 PARP1 (0.50) PRMT5MAOAMAOBSCN9ADAO
SCHEMBL28173425 0.78 DAO (0.48) MAOAMAOBSCN9ADAOLMNA
SCHEMBL16295073 0.78 DAO (0.48) MAOAMAOBSCN9ADAOLMNA
SCHEMBL17825205 0.78 DAO (0.45) MAOAMAOBSCN9ADAOLMNA
SCHEMBL17825233 0.77 PARP1 (0.64) MAOAMAOBDAOLMNATSHR
SCHEMBL15009931 0.77 SCN9A (0.51) MAOAMAOBSCN9ADAOROCK1
SCHEMBL16294141 0.76 DAO (0.48) MAOAMAOBSCN9ADAOLMNA
SCHEMBL15031985 0.75 PRMT5 (0.53) PRMT5WDR77ROCK1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 US disclosed
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors AMGEN INC. (US) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors SCN1A, SCN1B, CACNA1B PRMT5 4120/4885WDR77 2974/4885MAOA 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.